Federal Circuit Dismisses Amgen Appeal on Pfizer's Epogen Biosimilar
By Zachary Brennan -
Published 10 August 2017
The US Court of Appeals for the Federal Circuit on Thursday dismissed Amgen’s appeal related to a lawsuit over Pfizer’s Epogen (epoetin alfa) biosimilar.
Categories: News, US, FDA, Biologics and biotechnology, Compliance, Regulatory intelligence, Regulatory strategy
Tags: Epogen, epoetin alfa, complete response letter, Pfizer, Amgen
FDA Researchers Make Case for More Transparency When Drugs are Rejected
By Alexander Gaffney, RAC -
Published 12 June 2015
When the US Food and Drug Administration (FDA) finds reason not to approve a drug, it issues what is known as a Complete Response Letter (CRL) indicating its reasons for withholding approval and explaining which additional data might support an approval decision. Publicly-traded companies almost always communicate the issuance of these letters to the public, and generally summarize the points made by FDA in the letter. But how often do those companies tell the whole truth to their stockholders?
Categories: News, US, CDER, Biologics and biotechnology, Drugs, Regulatory strategy, Submission and registration
Tags: CRL, Complete Response Letter